Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery. 2008

Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
Division of Orthopedic Surgery, District Hospital Baden, Baden, Switzerland.

The rate of bleeding complications after major orthopedic surgery approximates 2%. It is unclear whether a systematic switch of routine thromboprophylaxis has an impact on the rate of postoperative bleeding complications. We analyzed prospectively recorded postoperative bleeding complications and symptomatic venous thromboembolic events in 8,176 consecutive orthopedic patients at the Schulthess Clinic Zurich during a systematic switch of thromboprophylaxis from nadroparin to enoxaparin in the year 2004. Overall, 3,893 patients received nadroparin in the first nine-month observation period before the switch and 4,283 patients received enoxaparin in the second nine-month observation period after the switch. Overall, 96 (2.5%) patients in the first period and 70 (1.6%) patients in the second period suffered a postoperative bleeding complication requiring surgical revision, puncture, or transfusion (p < 0.01). Five objectively confirmed symptomatic venous thromboembolic events during hospitalization in the first period and three events in the second period were recorded. In conclusion, the switch of thromboprophylaxis in a large orthopedic clinic did not cause an increase of postoperative bleeding complications and therefore was accompanied by high patient safety.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017762 Nadroparin A heparin fraction with a mean molecular weight of 4500 daltons. It is isolated from porcine mucosal heparin and used as an antithrombotic agent. (From Merck Index, 11th ed) CY 216,CY-216,Fraxiparin,Fraxiparine,LMF CY-216,Nadroparin Calcium,Nadroparine,CY216,Calcium, Nadroparin,LMF CY 216,LMF CY216

Related Publications

Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
January 2008, Drugs & aging,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
February 2014, Thrombosis and haemostasis,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
June 2013, Best practice & research. Clinical haematology,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
April 2016, British journal of clinical pharmacology,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
October 2018, British journal of clinical pharmacology,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
January 1996, Drugs,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
July 1997, American journal of surgery,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
December 2010, Expert review of pharmacoeconomics & outcomes research,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
June 2007, Thrombosis and haemostasis,
Urs Kistler, and Inès Kramers-de Quervain, and Urs Munzinger, and Nils Kucher
May 1998, Anaesthesia,
Copied contents to your clipboard!